Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
206actual
Sites
65
Countries
Belgium, France, Georgia +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-26 | actual | When the study began enrolling |
| Primary completion | 2026-05-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-29 | actual | The whole study's end, after follow-up |
| First posted | 2020-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Cancer
Interventions
- Drug: retifanlimab — also filed as INCMGA00012
- Drug: epacadostat
- Drug: pemigatinib
- Drug: INCAGN02385
- Drug: INCAGN02390
Primary outcome
what the primary-completion date above is the date OFGroup A - Objective Response Rate
measured up to 2.5 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed